Canada's challenge for medtech
Success to obtain risk capital is
low in medtech
40% of startups fail
at securing early stage
investment
BARRIERS & ISSUES
- Lack of understanding of commercial pathway for technical founders
- Lack of accessing to funding to both dilutive & non-dilutive funding sources
The EARLi-Tech Assessment:
A Detailed
Investor Ready
Due Diligence
Report to Guide Your Startups
- Detailed investment memo from three accelerator programs
- Business, Clinical and Regulatory Assessments from world-leading experts
EARLi-Tech Program Overview
Due Dilligence Packet from Canada’s Leading Incubators
Diligence
Report
Providers
Business Strategy
Market or patent or competition research
Regulatory and Clinical Strategy Report
Regulatory and Clinical Strategy Report
KOL landscape overview
Provided key insights into product design
Diligence
Report
Providers
Cost
EARli-Tech
X
X
X
X
X
X
X
$30k
Other Reports
X
X
X
x
x
x
x
> $100k
Diligence Report Providers
EARli-Tech
Other Reports
Diligence
Report
Providers
X
X
Business Strategy
X
X
Market or patent or competition research
X
X
Regulatory and Clinical Strategy Report
X
Regulatory and Clinical Strategy Report
X
KOL landscape overview
X
Provided key insights into product design
X
Cost
$30k
> $100k
We Can Deliver More for our Startups
How it Works
Scope Item
Description
1
Intake Meeting (1 hour)
- Review and train on product, internal documents, IFU documents and current client list and strategy
- Strategic Brainstorm
2
Requirements Gathering (3 hours)
- Review of strategy and define scope of work of report
- Review scope of work and deliverables of report with startup
3
Due Diligence Report (25 Pages)
- Business Commercialization Pathway
- Health economics
- Needs assessment
- Regulator overview and roadmap
- Clinical trial roadmap
- Clinical Commercialization Pathway
- Patient recruitment
- Facility Close
- Data close
- Ethics
- PI search
- Clinical trial design
